Daniel Babu P.
Head, PAMID
Daniel.babu@dae.gov.in
022-22862505

सत्यमेव जयते
भारत सरकार
Government of India
परमाणु ऊर्जा विभाग
Department of Atomic Energy

अणुशक्ति भवन
छत्रपति शिवजी महाराज मार्ग,
मुंबई - 400001
Anushakti Bhavan
Chhatrapati Shivaji Maharaj Marg,
Mumbai - 400 001

Ref: 13(1)/2023/PAD

December 12, 2023

PRESS RELEASE NO. 10/2023

Breakthrough Nutraceutical AKTOCYTE by the Department of Atomic Energy Set to Transform Cancer Care

In a breakthrough towards enhancing the quality of life for cancer patients undergoing radiotherapy, scientists from Department of Atomic Energy and M/s. IDRS Labs Pvt. Ltd. Bengaluru have joined hands to develop AKTOCYTE tablets. Experts from Bhabha Atomic Research Centre, Mumbai; Tata Memorial Hospital, Mumbai; Advanced Centre for Training Research and Education in Cancer, Navi Mumbai collaborated with the IDRS Labs with a primary aim of minimizing the side effects of radiotherapy.

The AKTOCYTE tablets have shown remarkable results, particularly in pelvic cancer patients suffering from radiotherapy-induced Cystitis (Blood in urine). Patients treated with AKTOCYTE tablets demonstrated an extraordinary recovery, eliminating the need for surgical removal of the urinary bladder. The tablets, designed as an adjuvant to cancer radiotherapy, regenerative nutraceutical, immunomodulator, and antioxidant, mark a significant advancement in cancer care.

AKTOCYTE has received approval from the Food Safety and Standards Authority of India (FSSAI), operating under the Ministry of Health & Family Welfare, Government of India. This regulatory clearance emphasizes the safety and compliance of AKTOCYTE tablets, providing assurance to both healthcare professionals and patients about its efficacy and quality.

Remarkable Recovery in Pelvic Cancer Patients: AKTOCYTE tablets have demonstrated exceptional efficacy in pelvic cancer patients undergoing radiotherapy, showcasing significant recovery and eliminating the need for surgical interventions.

....2...

Versatile Applications: The tablets serve as more than just a supplement. AKTOCYTE is positioned as an adjuvant to cancer radiotherapy, a regenerative nutraceutical, an immunomodulator, and an antioxidant, showcasing its versatility in cancer care.

Regulatory Approval: The approval by FSSAI underscores the commitment to safety and quality standards, providing healthcare professionals and patient's confidence in the reliability of AKTOCYTE tablets.

Market Availability: Anticipated to hit the market in January 2024, AKTOCYTE tablets are poised to become a transformative addition to cancer treatment protocols.

The collaboration between the institutions of DAE and industry has been instrumental in bringing this breakthrough to fruition. The development marks a pivotal moment in the convergence of scientific innovation and practical solutions for cancer care.

(Daniel Babu P.)

Collaboration between Scientists from Department of Atomic Energy and Industry Paves the Way for Improved Quality of Life in Cancer Patients